Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a
central focus for engaging the immune system in the fight against cancer. Basic science …

The balance of programmed death-1 (PD-1)-expressing CD8+ T cells and regulatory T
(Treg) cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 …

Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

Immune checkpoint blockade is able to induce durable responses across multiple types of
cancer, which has enabled the oncology community to begin to envision potentially curative …

Regulatory T cells (Tregs) are abundant in tumor tissues, raising a question of whether
immunosuppressive tumor-infiltrating Tregs (TI-Tregs) can be selectively depleted or …

The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Having a hypoxic microenvironment is a common and salient feature of most solid tumors.
Hypoxia has a profound effect on the biological behavior and malignant phenotype of …